SA PRO
Free Account
Avidity Biosciences, Inc.RNANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 53% recommend buying.

Consensus Rating
Buy
19 analysts·Moderate coverage
53%
Rating Distribution
Strong Buy
00%
Buy
1053%
Hold
947%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case
$72.00
-1%
Consensus
$74.67
+3%
Bull Case
$96.00
+32%
Price Range19 analysts
Low
Consensus
High
$72.00
$96.00
Current Target
Current Price
$72.74
Upside to Target
$1.93

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 18, 2025Evercore ISI
Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI
Target:$72.00
-0.2%from $72.11
Oct 28, 2025Chardan Capital
Avidity Biosciences downgraded to Neutral from Buy at Chardan
Target:$72.00
+2.9%from $70.00
Oct 28, 2025RBC Capital
RBC Capital Downgrades Avidity Biosciences (RNA) to Sector Perform
Target:$72.00
+2.9%from $70.00
Oct 28, 2025Loop Capital Markets
Chardan Capital Markets Downgrades Avidity Biosciences (RNA) to Neutral
Target:$72.00
+2.9%from $70.00
Oct 27, 2025Leerink Partners
Avidity Biosciences downgraded to Market Perform from Outperform at Leerink
Target:$72.00
+2.9%from $69.94
Oct 27, 2025Roth Capital
Avidity Biosciences downgraded to Neutral from Buy at Roth Capital
Target:$72.00
+46.5%from $49.15
Oct 27, 2025Bernstein
Avidity Biosciences downgraded to Market Perform from Outperform at Bernstein
Target:$72.00
+46.5%from $49.15
Oct 27, 2025H.C. Wainwright
Avidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright
Target:$72.00
+46.5%from $49.15
Sep 17, 2025Roth Capital
Avidity Biosciences initiated with a Buy at Roth Capital
Target:$62.00
+54.8%from $40.06
Sep 10, 2025Cantor Fitzgerald
Avidity del-zota data 'highly encouraging,' says Cantor Fitzgerald
Target:$96.00
+106.9%from $46.40
Jul 11, 2025Evercore ISI
Avidity Biosciences price target raised to $70 from $60 at Evercore ISI
Target:$70.00
+122.6%from $31.45
Sep 24, 2024Goldman Sachs
Goldman Sachs Starts Avidity Biosciences (RNA) at Buy
Target:$59.00
+35.6%from $43.50
Jun 12, 2024Wells Fargo
Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)
Target:$50.00
+72.9%from $28.92

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance